novo nordisk oral semaglutide Improves Cardiovascular Risk Factors in Type 2 Diabetes FDA Approves First Oral GLP-1

This isn't about motivation

That direct route is the whole point, and its why a shot outperforms a pill for anyone with absorption challenges

The GLP-1 component reduces appetite signalling in the hypothalamus and slows gastric emptying

These symptoms typically emerge during dose escalation and often diminish over several weeks as tolerance develops

The ADAs new stepwise deintensification figure (Figure 13.2) and NICEs frailty prescribing algorithm give you a structured way to reduce treatment burden when the risks outweigh the benefits

This distinction may pave the way for a better understanding of the mechanisms behind such side effects and inform future research